Tyrphostin AG 537A competitive inhibitor of EGF receptor kinase autophosphorylation

Tyrphostin AG 537

Tyrphostin AG 537 is rated 5.0 out of 5 by 1.
  • y_2019, m_10, d_13, h_18
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.13
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_222388, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 87ms
  • REVIEWS, PRODUCT
5
1
4
0
3
0
2
0
1
0
Synonym: Bis-Tyrphostin
Application: A competitive inhibitor of EGF receptor kinase autophosphorylation
Purity: ≥98%
Molecular Weight: 448.4
Molecular Formula: C23H20N4O6
* Refer to Certificate of Analysis for lot specific data (including water content).

Tyrphostin AG 537 competitively inhibits EGF receptor kinase autophosphorylation.


References

Tyrphostins as molecular tools and potential antiproliferative drugs: A. Levitzki & C. Gilon; TIPS 12, 171 (1991), (Review)

Physical State :
Solid
Solubility :
Soluble in DMSO (10 mg/ml).
Storage :
Store at -20° C
Melting Point :
349.84° C (Predicted)
Boiling Point :
901.65° C at 760 mmHg (Predicted)
Density :
1.46 g/cm3 (Predicted)
Refractive Index :
n20D 1.71 (Predicted)
IC50 :
Epidermal growth factor receptor kinase autophosphorylation : IC50 = 400 nM; Antiplasmodial activity against Plasmodium falciparum 3D7 : IC50 = 1.58 µM; Antiplasmodial activity against Plasmodium falciparum HB3 : IC50 = 1.58 µM; Dynamin I: IC50 = 1.7 µM (human); Plasmodium falciparum: IC50 = 2.5 µM
pK Values :
pKa: 8.51 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
WGK Germany :
3
PubChem CID :
5329255
MDL Number :
MFCD00236440
SMILES :
C1=CC(=C(C=C1/C=C(/C(=O)NCCCNC(=O)/C(=C/C2=CC(=C(C=C2)O)O)/C#N)\C#N)O)O

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 188ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Hudry Hudry-Clergeon, H. et al. (PubMed 15791001) reported that treatment of cells with platelet-activating factor induced a rapid time- and dose-dependent increase in tyrosine phosphorylation of a subset of proteins, including the VE-cadherin, the latter effect being prevented by the tyrosine kinase inhibitor Tyrphostin AG 537. -SCBT Publication Review
Date published: 2015-04-29
  • y_2019, m_10, d_13, h_18
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.13
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_222388, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 66ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.